ENXTPA:PCA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PCAS SA develops and produces complex molecules for life sciences and technologies worldwide.


Snowflake Analysis

Fair value with mediocre balance sheet.


Similar Companies

Share Price & News

How has PCAS's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PCA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.1%

PCA

-0.4%

FR Life Sciences

4.7%

FR Market


1 Year Return

-34.5%

PCA

50.2%

FR Life Sciences

-3.8%

FR Market

Return vs Industry: PCA underperformed the French Life Sciences industry which returned 51.1% over the past year.

Return vs Market: PCA underperformed the French Market which returned -4.4% over the past year.


Shareholder returns

PCAIndustryMarket
7 Day7.1%-0.4%4.7%
30 Day1.1%6.8%12.1%
90 Day-9.0%24.3%-1.8%
1 Year-34.5%-34.5%51.0%50.2%-2.1%-3.8%
3 Year-45.1%-45.2%103.8%99.6%8.8%0.05%
5 Year126.6%120.3%260.1%236.9%26.5%10.3%

Price Volatility Vs. Market

How volatile is PCAS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PCAS undervalued compared to its fair value and its price relative to the market?

31.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PCA (€9.1) is trading below our estimate of fair value (€13.19)

Significantly Below Fair Value: PCA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PCA is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: PCA is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PCA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PCA is good value based on its PB Ratio (1.5x) compared to the XE Life Sciences industry average (5.4x).


Next Steps

Future Growth

How is PCAS forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PCAS has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has PCAS performed over the past 5 years?

-53.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PCA is currently unprofitable.

Growing Profit Margin: PCA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PCA is unprofitable, and losses have increased over the past 5 years at a rate of -53.8% per year.

Accelerating Growth: Unable to compare PCA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PCA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (13.4%).


Return on Equity

High ROE: PCA has a negative Return on Equity (-16.76%), as it is currently unprofitable.


Next Steps

Financial Health

How is PCAS's financial position?


Financial Position Analysis

Short Term Liabilities: PCA's short term assets (€117.7M) exceed its short term liabilities (€107.3M).

Long Term Liabilities: PCA's short term assets (€117.7M) exceed its long term liabilities (€74.2M).


Debt to Equity History and Analysis

Debt Level: PCA's debt to equity ratio (78.3%) is considered high.

Reducing Debt: PCA's debt to equity ratio has increased from 75.6% to 78.3% over the past 5 years.

Debt Coverage: PCA's debt is well covered by operating cash flow (50.4%).

Interest Coverage: Insufficient data to determine if PCA's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is PCAS's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PCA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PCA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PCA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: PCA is not paying a notable dividend for the French market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PCA's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Pierre Luzeau (54yo)

0.25

Tenure

Mr. Pierre Luzeau serves as Chief Executive Officer of NOVACAP SASU since 2007 and Member of Management Board of NOVACAP SASU. Mr. Luzeau joined Novacap SASU in 2007 and served as its Chairman, President a ...


Leadership Team

NamePositionTenureCompensationOwnership
Pierre Luzeau
Chairman & Interim CEO0.25yrno datano data
Éric Moissenot
Deputy Managing Director of Finance & Administrationno datano datano data
Gérard Guillamot
Scientific Director3.25yrsno datano data
Corinne Fischer-Gode
Director of Human Resourcesno datano datano data
Didier Schneider
Director of Chemicals Performance and Chairman Protéusno datano datano data
Christophe Eychenne-Baron
Head of Research & Development3.25yrsno datano data
Sébastien Taillemite
Deputy Managing Director of BU Fine Chemistryno datano datano data
Juliette Martin
Chief Executive Officer of Protéusno datano datano data
Laurent Alexandre
Director of Pharmaceutical Synthesis - Generic Active Pharmaceutical Ingredientsno datano datano data

3.3yrs

Average Tenure

Experienced Management: PCA's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Pierre Luzeau
Chairman & Interim CEO0.25yrno datano data
Didier Schneider
Director of Chemicals Performance and Chairman Protéusno datano datano data
Alain De Salaberry
Independent Director14.67yrs€9.00k0.00073% 912.9
Jacqueline Lecourtier
Director6.25yrs€15.00k0.00073% 912.9
Vincent Milhau
Director3yrsno datano data
Vanessa Michoud
Director3yrsno datano data
Marc De Rocquefeuil
Director3yrsno datano data
Pauline de Robert Hautequère
Independent Director3yrs€13.50kno data

3.0yrs

Average Tenure

57yo

Average Age

Experienced Board: PCA's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PCAS SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PCAS SA
  • Ticker: PCA
  • Exchange: ENXTPA
  • Founded: 1962
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €125.049m
  • Shares outstanding: 13.74m
  • Website: https://www.pcas.com

Number of Employees


Location

  • PCAS SA
  • BP 181 - 23 Rue Bossuet
  • Z.I. La Vigne aux Loups
  • Longjumeau
  • Ile-de-France
  • 91160
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCAENXTPA (Euronext Paris)YesCommon SharesFREURApr 1995
0NF7LSE (London Stock Exchange)YesCommon SharesGBEURApr 1995
PCAPBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURApr 1995

Biography

PCAS SA develops and produces complex molecules for life sciences and technologies worldwide. It offers chemical and analytical development services for clinical active ingredients or advanced intermediates; and custom manufacturing services for pharmaceutical active ingredients or key intermediates. The company also engages in the development and production of active pharmaceutical ingredients; and production of reagents, building-blocks, and synthesis intermediates, as well as drug delivery systems, excipients, and biomaterials. In addition, it provides advanced specialty solutions, such as electronic materials, polymers and monomers, and cosmetic ingredients, as well as custom manufacturing services to various industries operating in sectors, including microelectronics, energy, environment, industrial processes, special polymers, and personal well-being. Further, the company offers performance chemicals comprising industrial lubricating additives, long term corrosion protection products, greases, and bio-sourced lubricants, as well as custom manufacturing and tooling services. PCAS SA was founded in 1962 and is headquartered in Longjumeau, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/04 20:45
End of Day Share Price2020/06/04 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.